Jongseong Kim, Founder and CEO of OncoLab Co., Ltd., presented the ANGel platform at the 2026 Gordon Research Conference on Antibody Biology and Engineering held in Ventura, California.
His presentation, titled “Subcutaneous Antibody-Conjugated Microgel (ANGel) Platform Enabling Combination Immunotherapy for Refractory Solid Tumors,” was featured in the conference session “Unique Antibody Formats and Multispecifics.”
He was also invited to serve as Co-Discussion Leader for the conference’s “Antibody Drug Conjugates” session, leading scientific discussion on next-generation antibody therapeutics.